articleTop 1% cited
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Clinical Cancer Research · 2015 · Vol. 21(19) · pp. 4286–4293
Amita Patnaik✉Soonmo Peter KangDrew RascoKyriakos P. PapadopoulosJeroen Elassaiss‐SchaapMuralidhar BeeramRonald DrenglerCong ChenLon SmithGuillermo EspinoKevin GergichLiliana DelgadoAdil Daud(University of California, San Francisco)Jill A. LindiaXiaoyun LiRobert H. PierceJennifer H. YearleyDianna WuOmar LaterzaM. LehnertRobert IannoneAnthony W. Tolcher
Abstract
Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors. The lowest dose with full potential for antitumor activity was 2 mg/kg every 3 weeks.
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchColorectal Cancer Treatments and StudiesPembrolizumabMedicinePharmacokineticsResponse Evaluation Criteria in Solid TumorsMelanomaPharmacodynamicsDiscontinuationToxicityInternal medicineGastroenterology
MeSH terms
AdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasm StagingNeoplasmsTreatment OutcomeDrug MonitoringMolecular Targeted TherapyProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, Humanized
Citations
774
FWCI
30.03
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
European Journal of Cancer · 2017 · 534 citations
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Frontiers in Pharmacology · 2017 · 465 citations
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Annals of Oncology · 2017 · 898 citations
References
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
The EMBO Journal · 1992 · 3,162 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Immunity · 1999 · 2,706 citations
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
European Journal of Immunology · 2002 · 665 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research · 2009 · 3,204 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.